T wenty-five percent to 50% of community-dwelling seniors suffer from pain that interferes with their ability to function normally. [1] [2] [3] The older adult is much more likely to have pain than younger individuals. 4 The prevalence of pain in the nursing home is 45% to 80%, with analgesics being used in 40% to 50% of residents. [5] [6] [7] [8] Since most older patients have at least one chronic condition and take multiple medications, prescribing for the senior patient in pain can be a daunting task indeed. 9 Probably the most distressing of symptoms for patients and caregivers is pain. For physicians and other healthcare providers who have entered the field of medicine to help relieve suffering, it can be extremely frustrating to fail to provide adequate pain management for their patients. Unfortunately, this is all too often the case. In 1994, a study from the Eastern Cooperative Oncology Group showed that 41% of cancer patients suffered from inadequate pain management. 10 The top risk factor for inadequate pain management in that study was being over 70 years old.
Reasons for inadequate pain control by clinicians include lack of training, inadequate pain assessment, and reluctance to prescribe opioids. 11, 12 The goal of this article is to provide some practical guidance to ensure pain relief among older patients This can be achieved by focusing on recognizing the presence of pain and evaluating interventions that have been standardized. 13, 14 Implementation of these recommendations will provide early and lasting relief.
FACTORS TO CONSIDER

Age-Related Pharmacokinetics
Drug distribution usually is different in older patients as compared with younger patients because of changes in blood flow to organs, protein binding, and body composition that occur with aging. 15 Most analgesics have some dependence on hepatic metabolism. Some rely more heavily on the cytochrome P450 system than others, even within the same class of drugs. For example, the selective cyclooxygenase (COX-2) inhibitor celecoxib is much more dependent on the cytochrome P450 system than its counterpart rofecoxib. 16 Like all nonsteroidal anti-inflammatory drugs (NSAIDs), both have renal effects that must be kept in mind when prescribing to seniors.
Affective/Cognitive Components
Depression is often overlooked in older patients and requires consideration when managing patients with pain. 17 Investigation of the association between depression and pain complaints in older patients has revealed that initial control of depression greatly facilitates pain management. One should avoid the misconception that the pain itself is the sole cause of depression and that controlling the pain will eliminate the depression. If depression is not addressed aggressively, interventions to manage pain are unlikely to be successful. Because tricyclic antidepressants, for example, nortriptyline and desipramine, also may be useful in neuropathic pain, such agents should be considered when such pain develops. Amitriptyline should be avoided because of its associated risk for adverse events such as falls, mental status change, orthostatic hypotension, and other anticholinergic-related side effects. 18 Secondary gain, mental focus, prior experience, and anxiety also should be taken into account. While these concepts have not been well studied in seniors, it is reasonable to consider that a patient who receives a visit from her daughter every time she has pain, is likely to have some secondary gain from her pain that will make pain management much more difficult. Secondary gain should be identified and appropriate measures taken to remove that secondary gain or to restructure it so that it is associated with pain relief. For example, the daughter who visits the mother in the nursing home with pain stays for longer periods of time when there is pain relief and makes an effort to make additional visits between painful episodes, thus minimizing or removing the secondary gain from the pain setting.
The patient who has little to consider other than pain may also find that pain to be more difficult to control. A confused senior who becomes disoriented and falls in the process of a panicked exit from an unfamiliar setting may not complain of pain from the injury until after the fear has subsided and calm has returned. Mental focus seems to be of importance for older as well as younger adults, although controlled studies in this area are lacking. Nonetheless, it is for this reason that interventions that channel concentration away from pain may prove useful. Patients who are lying in bed with their focus on little else other than their next pain pill may be given music, books on tape, or even tapes of the waves crashing on the seashore to help change their mental focus away from the pain. While pain diaries may be helpful, the constant question of "Are you in pain?" makes it difficult not to focus on pain. Paradoxically, such questioning in and of itself may make pain control more difficult. Once periods of pain relief have been established, patients using a pain diary should be instructed to record periods of pain or discomfort rather than recording pain status on a regular schedule. It is also preferable, therefore, to focus on function or other goals. For example, one develops a goal of improving comfort to a level that allows the patient to get to the bedside commode or to the bathroom, or to walk in the hallway. Questioning can focus on function, "Were you able to walk in the hall?"
Prior experience, either personal or vicarious, can have a significant impact on one's ability to cope with pain. The apprehension that some patients experience because they have seen a family member suffer, for example, a previous cancer course where hospice was not instituted, may make pain management much more difficult. Anxiety itself can augment a pain response and so combining agents such as anxiolytics with an opioid can lead to better pain control. 19 However, some anxiolytics such as hydroxyzine, are associated with anticholinergic effects that may lead to mental status change, orthostatic hypotension, and an increased risk of falls and should be used judiciously in seniors.
TREATMENT
Obtaining a proper history, including the onset, duration, characteristics, and intensity of pain and a description of any affective and cognitive components involved in the pain is the first step in determining appropriate treatment. After performing a thorough physical examination, recognizing that older individuals often may present with relatively subtle findings as manifestations of very serious disease, a treatment plan can be devised. Removal of the underlying cause to cure pain is ideal, but this often is not possible and is not always 100% efficacious. Even in joint replacement to provide pain relief from osteoarthritis, ongoing postoperative pain requiring chronic treatment is common. With cancer, cure may not be an option and the focus is on palliation.
Regardless of the etiology of pain, a clinician should consider both nonpharmacologic interventions and pharmacologic ones. In an older population, where the risk of adverse events is higher, the nonpharmacologic options will usually be less costly and cause fewer side effects.
Regardless of the modality used, measures to palliate the nociceptive components of pain usually involve one of three strategies: (1) suppress the release of products from tissue damage that may stimulate C-fibers; (2) increase the release of endogenous opioids through stimulation of appropriate feedback neuronal pathways; and (3) provide exogenous medication that binds on receptors that can modify noxious response either centrally or peripherally.
Nonpharmacologic Interventions
Healthcare professionals may overlook some common nonpharmacologic interventions, such as cold (which can suppress the release of products from tissue damage) and warmth (which stimulates production of endogenous opioids). 20 Given the high benefit to risk ratio of such interventions, and noting that each may lead to the release of endogenous opioids, it is worth adding such nonpharmacologic measures when appropriate. Endogenous opioid release occurs with other interventions such as transcutaneous electrical nerve stimulation, percutaneous electrical nerve stimulation, and acupuncture as well. 21, 22 The role of mental focus and anxiety in pain management is important, and relaxation techniques, biofeedback (particularly with vascular headaches), or hypnosis may be useful. Physical therapy and occupational therapy bring a variety of modalities, including the use of braces or splints, changes in biomechanics, and exercise itself, all of which have been demonstrated to improve pain relief. 23, 24 Nerve blocks and tumor site radiation may also be helpful in a variety of pain settings. [25] [26] [27] Recently, interventions with low-strength static magnets have stirred interest. Controlled trials have indicated some benefit over placebo in controlling pain from diabetic neuropathy and post-polio syndrome. 28 Not all studies with magnets have shown benefit, however. 29 Regardless, alternative or complementary medical interventions should be recognized as options for patients. 30 These options exist with or without physician rec- 
Pharmacologic Interventions
While efficacy is of major importance when considering pharmacologic interventions, especially in the older adult, cost and safety must also be considered. Achieving pain control in the hospital may be of little merit if the patient goes home and cannot afford the medications prescribed because the out-of-pocket costs are prohibitive. A patient may not tell a clinician that the medication is not affordable. Or a patient may withhold the purchase of other vital commodities, such as nutrition or heat, which may be sacrificed to purchase medicine that is needed to control pain. Such scenarios must be considered whenever a patient's health plan covers medications in the hospital but not on an outpatient basis, and whenever patients obtain excellent pain control in the acute care setting (where medications are covered), but inadequate pain management once discharged from the hospital (i.e., no plan is in place to cover outpatient prescriptions). A related circumstance occurs when a patient who has not been taking medications as prescribed comes into the hospital for an acute problem and, for the first time, begins receiving the dose and schedule prescribed. This can result in the patient receiving more medication than is necessary or than can be adequately metabolized and removed. The patient is then at risk for adverse events, including injury and even death. Such sequelae usually result in prolonged hospital stays and great costs overall.
Other issues that must be considered among older adults include changes in drug metabolism, other disease comorbidity, and polypharmacy. 33 Few drug trials have adequately studied seniors, and prescribing for older patients may require dosing adjustments to account for altered pharmacokinetics and bioavailability that normally occur with age. This issue is compounded by disease comorbidities that may exacerbate normative aging changes. Finally, the process is complicated by having to consider interactions among a variety of other drugs. 34 On average, a 70-year-old takes seven different medications. [35] [36] [37] The addition of analgesics to a complex medication regimen is even more likely to cause drug interactions in an older individual. 37 For this reason, careful review of all medicines to eliminate any unnecessary medications from the drug regimen is always advised before adding a new agent, and should be an early focus when treating pain.
When deciding upon which pharmacologic agents to use, it is helpful to classify medications as nonopioids or opioids. The World Health Organization has advocated a three-step ladder for cancer pain, with the first step consisting of nonopioids. When these agents are unsuccessful in managing pain, the next pharmacologic intervention should involve opioid therapies. 38 At the next step, adjuvant nonopioid medications may be used to augment the response to an opioid medication. In severe pain, a course of nonopioid medication at the onset is not necessary. Instead, early use of opioids will be necessary to bring the pain into a tolerable range. Combination products, i.e., those that have an opioid combined with a nonopioid, should be avoided because of the limited dosing available due to the ceiling dose for the nonopioid, which may lead to severe side effects if excess medication is taken (see the discussion on acetaminophen below).
Nonopioids
Nonopioids are generally the first line of therapy for mild to moderate or "tolerable" pain, and acetaminophen is usually the first choice because it is relatively safe for older people. Because acetaminophen is included in many combination products, other drugs are metabolized through the liver, and hepatic disease is found in older patients, vigilance regarding both prescription and nonprescription medications containing acetaminophen is important. For example, a patient who is prescribed two Tylox TM , oxycodone with 500 mg acetaminophen, every six hours, will ingest 4 grams of acetaminophen-the maximum recommended dosage. Higher doses of acetaminophen are not associated with better analgesia and can be toxic. For example, inadvertently taking two extra-strength Tylenol TM tablets (500 mg acetaminophen each) for breakthrough pain twice in a 24-hour period, would result in a total of 6 grams of acetaminophen ingestion, the dose above which there is increased risk of toxicity. 39 In patients who might abuse alcohol, caution with medications that have large amounts of acetaminophen becomes even more important. 40, 41 Nevertheless, acetaminophen is generally very well tolerated in older people and has stood up well against NSAIDs, which generally have a much worse gastrointestinal side effect profile and may be considerably more dangerous in older people. [42] [43] [44] [45] NSAIDs on the market all involve concerns related to hypertension and renal effects. 46 A new class of NSAIDs that seem to have a better safety profile based on clinical trials and theoretical advantages is the class of cyclooxygens (COX)-2 inhibitors (which inhibit the production of prostaglandins associated with inflammation). 16 By limiting COX-1 activity, the production of cytoprotective prostaglandins (e.g., Prostanoids PGE 2 and PGI 2 ) is protected. 47 Gastrointestinal safety is attributed to this limiting of constitutively expressed COX-1 activity in the gastric mucosa. 48 Rofecoxib and celecoxib are the two highly-selective COX-2 inhibitors that have been approved by the Federal Drug Administration (FDA). While FDA labeling still recognizes some gastrointestinal risk, the key clinical distinctions found in these COX-2 inhibitors seem to be a dramatically diminished gastrointestinal adverse event profile and a minimal anticoagulation effect (approximately 10% increase in prothrombin time when taken with warfarin). 49 The safer profile comes without a compromise in analgesia when compared with other NSAIDs. 50, 51 Unlike celecoxib, rofecoxib comes in liquid and tablet form and is not contraindicated for patients who have sulfa allergies. These two distinctions will be relevant to anyone prescribing medication for a frail, older population. Onset of action is also more rapid and duration of effect longer for the rofecoxib. 52 Neither agent is contraindicated with warfarin an-ticoagulation. Since these agents do not effectively inhibit thromboxane (a result of COX-1 inhibition), an antiplatelet cardioprotective benefit is less likely to occur. Furthermore, any adverse event associated with COX-2 inhibition from traditional NSAIDs, for example, renal toxicity, including hypertension and edema, can also be anticipated in COX-2 selective agents.
The antiprostaglandin activity of NSAIDs has been touted as the basis for these agents being effective, particularly in metastatic bone pain. 53 Other agents that have received attention with regard to metastatic bone pain have included radionuclides (e.g., strontium-89 and samarium-153 lexidronam) and the bisphosphonates (e.g., pamidronate). 54 Radionuclides are recommended in metastatic bone pain where survival is anticipated to exceed three weeks and other, more conventional treatments have failed. Radionuclides take about a month before they are effective. In about 90% of cases, additional adjuvant medications will be needed to control pain. When effective, intervention should last up to 6 months. Most patients will require more than a single treatment and it should be noted that each treatment costs in excess of $2000.
Bisphosphonate therapy is also useful in managing metastatic bone pain. Improvement may be seen as early as 5 days after administration of pamidronate (90 mg intravenously once a month) for skeletal events associated with multiple myeloma or breast cancer. 55, 56 Of the bisphosphonates available in the United States, pamidronate has been studied the most extensively as a treatment for metastatic cancer. 57 Administration should be over 3 to 4 hours to minimize associated adverse events, which usually come in the form of transient flu-like symptoms. Hypocalcemia and temporary lymphocyte suppression have also been seen. 39 One could consider other available bisphosphonate agents such as etidronate, alendronate, or risedronate in doses recommended for Paget's disease to have benefit in metastatic bone pain as well. 58 Vitamin D is also likely to be helpful in some pain situations. Vitamin deficiency, which is likely to be present in older homebound patients, especially in the presence of anti-epileptics or fat malabsorption syndromes, should also be recognized as a potential cause for deep musculoskeletal pain or superficial light pressure pain. 59, 60 Vitamin D and calcium have also been shown to decrease fracture rates, which are a source of pain themselves. 61 Research has demonstrated that perhaps more than one-third of nursing home subjects who have been confined indoors for more than 6 months and are age 65 and older, and more than half of such community-dwelling subjects, are likely to suffer from vitamin D deficiency. 62 Because a single treatment of 100,000 I.U. (Supplied as two 50,000 I.U. capsules) of vitamin D is likely to restore a patient to normal vitamin D status and resolve pain associated with deficiency of this vitamin, one does not want to overlook this cause of pain.
Topical agents are also available for site-specific pain. Capsaicin has been demonstrated to be particularly useful for neuropathy. It should be started at the lowest dose recommended (0.025% every 6 hours). The use of a topical spray, for example, Solarcaine TM , may diminish the burning sensation that some people feel when capsaicin is applied without interfering with its efficacy. Because this agent interferes with the reuptake of substance P, capsaicin should be used on a regularly dosed schedule of every 6 hours. Skipping doses will result in reaccumulation of substance P and, thus, a return of pain.
Calcitonin has been shown in clinical trials to relieve pain associated with vertebral compression fractures. 63 The mechanism of action for this pain relief is unclear but speculation ranges from an effect on calcitonin-gene-peptide to both central and peripheral actions. 64 Arthritic pain management has seen a myriad of products gain attention over the last few years. Some are disease-modifying agents like leflunamide, which inhibits the formation of pyrimidines by inhibiting the formation of orotate from dihydroorotate. Others include hyaluronanate injections designed to stimulate endogenous hyaluronanate synthesis. While the improvement in pain is better than with placebo, the medications are expensive (about $200 per a 2-ml dose) and may themselves cause an inflammatory response. 65 Etanercept, which directly affects tumor necrosis factor (TNF), is another agent approved for pain in rheumatoid arthritis. 66 Usually, this is administered as a 25-mg subcutaneous injection twice weekly. A local reaction may occur but usually dissipates over time.
Tramadol is another agent available to help control pain and, except in a substance-abuse population, should have a low tolerance problem and may be beneficial in a variety of pain situations. It is important to start low with this medication and gradually increase. Starting at 50 mg every 12 hours is reasonable and personal anecdotal experience indicates that a lower frequency of adverse events (which may occur in one-third of patients otherwise) may be achieved using such a strategy. Regardless, tramadol is not a substitute for opioids when they are indicated. Even at the maximum recommended tramadol dose of 100 mg every 6 hours, the equianalgesic effect would not exceed a single 60-mg dose of controlled-release morphine over the course of a day. 67 Like acetaminophen, the mechanism for analgesia is not fully understood with tramadol. There is exceedingly weakreceptor binding (1/5000th of morphine) and this by no means accounts for the bulk of its analgesic effect (see "Adverse Events" for discussion of -receptors).
Other agents, such as tricyclic antidepressants, some anti-epileptics (e.g., clonazepam, carbamazepine, gabapentin, and phenytoin), and mexilitine, have also been recommended for neuropathic pain. [68] [69] [70] [71] [72] Effective doses for pain are usually below those needed for the treatment of depression or seizures (see Figure 1) .
As a final caveat, it should be stressed that all of the nonopioids should be considered as first-line treatment of pain. Just as the World Health Organization and the Agency for Health Care Policy and Research (now the Agency for Healthcare Research and Quality) recommend that if cancer pain does not respond to non-opioids initially, the next step should be to use opioids, 38, 68 this principle should be extended to refractory nonmalignant pain. In settings where nonopioids do not provide adequate relief and other modes of pain control have resulted in therapeutic failures, it is unreasonable to withhold opioids that can relieve suffering and restore function and comfort. In many circumstances, nonopioids can be continued with the new opioid regimen, providing pain relief at lower opioid dosing (see "Adjuvant Analgesics" section). 
Opioids
Opioids have been used for centuries to control pain. Understandably, there are many misconceptions about opioids. It is necessary to recognize that patients are likely to have opinions about opioids that may not be based on fact. Any time one prescribes any opioids, it is prudent to articulate some of the data associated with opioid use in pain management. Addressing some of the myths about morphine, and opioids in general, will be helpful toward eradicating stigma for both prescribers and patients. This will likely improve compliance and relieve a great amount of suffering in the future.
It is important to explain that even chronic use of morphine rarely leads to addiction when used to control pain. 73 It is also important to distinguish between a physiologic dependence or tolerance (both can be expected with chronic opioid use) and addiction (which rarely occurs). Addiction involves a psychological component wherein individuals will crave a medication and place themselves in harm's way or participate in self-destructive behavior to acquire a drug. The older patient may contribute to the high incidence of undertreated pain because of exaggerated concerns or fears about adverse effects from or addiction to pain medications, including medications not associated with the potential for addiction. In reality addiction risk with opioids is low ( Ͻ 0.1%) when analgesics are used for acute pain in patients who are not substance abusers. 74 While many would consider the point irrelevant in a person with a terminal illness, the issue still may arise when a potent analgesic is required for comfort in the final days of life.
Tolerance to most adverse symptoms associated with opioids is likely to develop over time. An individual who has nausea and vomiting on morphine is likely to have those symptoms resolve as tolerance develops over the course of a few days to weeks. It is therefore important to minimize the nausea and vomiting through anti-emetic medications, rather than trying to switch to different opioids. (Often, 3 days or so after switching to different opioids, one can expect to select the "right" opioid analgesic as tolerance develops to opioid side effects in general.) Dosing adjustment (usually decreasing it) also may help. Once pain is under control and anxiety levels have declined, it is common to need a smaller maintenance dose than that needed initially to bring pain under control. Unlike nonopioid medications, opioids alone have no ceiling, thus dosing can continue to be increased as tolerance develops or pain worsens. A limitation can come if the prescribed opioid is a combination product that includes a nonopioid that has a ceiling for toxicity, for example, acetaminophen with codeine preparations.
Proper dosing of opioids can be achieved in older people by starting with a short-acting opioid and rapidly switching to a controlled-release formulation, with emphasis on regular dosing schedules. Solely "prn" dosing should be avoided. Instead, such dosing should be used only for rescue of breakthrough pain. A general rule is to increase regular dosages if "prn" medication is used three times over a 24-hour period. It is helpful to think of "prn" as standing for " p ain r elief n egligible," keeping in mind that regular dosing uses less narcotic and provides better pain relief. 75 However, it is important to inform patients that they may refuse a regularly scheduled medication if they feel that they do not need it or if they feel that they are developing undesired side effects. Such information needs to be relayed immediately to the attending physician. Close attention to patients (including assessment for change in cognition, physical finding, and pain) in the first 24 hours after an adjustment in medication will be helpful in pain control with minimal complications. Recommendations for increasing dosing are given below.
Patient-controlled analgesia (PCA), whether using oral or parenteral agents, can be most beneficial in a cognitively intact population, with the likelihood of the best pain control in conjunction with the least amount of opioid needed to control pain. PCA need not only be with subcutaneous, intravenous, or another type of high-tech pumping system. An oral long-acting agent such as morphine (the oral dose required is usually about 3 to 4 times greater than the parenteral dose needed for the same duration; see Table 1 ) or oxycontin in conjunction with a similar short-acting agent can also be used.
Most opioids can also be given in liquid form or through alternate administration routes, for example, subcutaneously or inhaled. While this may be helpful when encountering difficulty with a particular route of administration, it may be beneficial to change types and routes of administration as infrequently as possible. For this reason, controlled-release agents such as oxycodone or morphine (a controlled-release hydromorphone will soon be available as well) will be used more frequently in conjunction with short-acting agents that are the immediate-release versions of these same medications. This simplifies conversion to controlled-release medications because direct conversion can be done by adding up the amount of short-acting medication over the controlled-release medication's time-frame of scheduled dosing. For example, a patient who uses 30 mg of short-acting morphine every 4 hours can be anticipated to require 90 mg of controlled-release morphine every 12 hours.
In older people, opioids are often started at doses too low for pain relief with the expectation of titrating the doses upward to achieve relief at the minimum dose. In this scenario, increases should occur regularly and be made in 50% to 100% increments. Thus, a patient who obtains inadequate pain control from 60 mg of controlled-release morphine every 12 hours, should have the dose increased by 50% to 100% (to 90 mg to 120 mg) every 12 hours. It is important to recognize that some people will metabolize the medication more quickly, and if breakthrough pain occurs after 8 hours of adequate pain relief, the solution would be to increase the frequency of dosing to every 8 hours from every 12 hours rather than to increase the 12-hour dosage. A controlled-release morphine or controlled-release oxycodone should never be prescribed more frequently than every 8 hours. If breakthrough pain occurs after 3 or 4 hours, increase the amount of medication, maintaining the same dosing schedule. Other older individuals will metabolize medication more slowly and may need less frequent dosing at surprisingly low quantities of opioids, such as 15 mg to 30 mg of controlled-release morphine every 24 hours. A final point on dosing is that greater amounts of analgesic may be necessary initially to bring pain under control than to maintain control of pain.
Conversion from one route to another or from one type of opioid to another can be problematic. Close observation and assessment of pain status over the first 24 to 72 hours after making such changes is of paramount importance. For example, the package insert (Physicians Desk Reference) lists equianalgesic dosing of fentanyl 100 g/h equivalent to 60 mg per day of intramuscular (IM) morphine. 39 The route is obviously very important. A 200 g patch therefore would be equivalent to 120 mg/day of parenteral morphine or 480 mg to 720 mg of oral (P.O.) morphine. The package insert for oxycontin also lists 20 mg of morphine over 12 hours as equianalgesic to 25 g of fentanyl. This makes fentanyl 200 g/hour equianalgesic to 320 mg of P.O. morphine per day. Our experience has been that you are best somewhere in between these doses. The safest is always to go with the lower dose, with a very low threshold for using breakthrough medication whenever there is a change.
Great caution needs to be maintained to avoid overmedication when discontinuing a transdermal fentanyl patch. Since there continues to be an unchanged infusion rate and dose for 18 hours after removal of the patch (via a subcutaneous reservoir), when converting to oral opioids use lower doses and gradually increase over the course of 3 days until a steady state is reached. 76 Based on the need for breakthrough medication, a regular dosing schedule can be calculated.
Most opioids are available as liquids and many as rectal suppositories. Although not formulated as such (and not FDA approved) both controlled-release morphine and controlled-release oxycodone have been used as suppositories with clinical benefit. Additional caution is warranted with administration of controlled-release oxycodone in this manner because absorption may be increased by 30%. Regardless, only few patients will tolerate rectal suppositories for prolonged periods and this route should only be used on a temporary basis. Also, long-acting agents generally should not be crushed because crushing results in more rapid and unpredictable absorption. All too often controlled-release agents have been crushed for older patients who have difficulty swallowing pills. The potential dangers associated with this practice cannot be emphasized enough.
Meperidine has been associated with a host of adverse events in seniors and should be avoided in older people. 77 Meperidine leads to the formation of a metabolite, normeperidine, which accumulates beyond the analgesic duration of meperidine. Normeperidine acts as a central stimulant that lowers seizure threshold when used chronically. Additionally, meperidine has been associated with an increased risk of falls, likelihood of sedation, and psychotomimetic activity when compared with other opioids. 78, 79 The poor oral absorption of meperidine is another reason to avoid this medication. It has been common to combine meperidine with a product such as hydroxyzine, which is anticholinergic and can be associated with orthostatic hypotension and confusion. Such a combination can be exceedingly dangerous in a frail older population already susceptible to falls and alterations in cognitive function.
While -, -, and ␦ -opioid receptors are all associated with analgesia, only the -receptor binding produces euphoria, which may be particularly helpful in chronic pain where depression is quite common. For this reason opioids that target the -receptor are preferred. Other opioids that are antagonistic to the -receptor are less desirable, given the high prevalence of depression among people with chronic pain and the advantage of the euphoric component that occurs when the -receptor is bound. There is no role for agonist-antagonist agents. These generally block binding and create adverse events associated with other opioid receptor binding. 80 For example, pentazocine and similar agents (e.g., buprenorphine) have agonist and antagonist properties based on specific opioid receptor binding and blockade. Unfortunately, the agonist/antagonist agents antagonize -receptor binding (exactly the receptor that is most desirable in chronic pain conditions) and can be associated with severe withdrawal. There is an association with a psychotomimetic action and severe withdrawal from -receptor-binding opioids. Older patients may be particularly susceptible to mental status changes, in part because of the greater prevalence of diseases affecting cognitive function in this population. The combination products incorporating an opioid-receptor agonist and a different receptor antagonist have not been shown to be free of addiction potential, have not been demonstrated in rigorous trials to be of any advantage, and may be of considerable disadvantage when compared with centrally acting opioid analgesics that do not have antagonistic properties. 82 Transdermal fentanyl patches should generally be avoided as a first-line agent in older patients because absorption is unpredictable, being affected by differences in body temperature and subcutaneous fat and water in older patients as compared with younger adults studied in clinical trials. The fentanyl patch may be useful in a situation where oral medication cannot be administered and subcutaneous or other routes that require special pumping devices are too cumbersome. However, an opioid-naive person should never be started on more than 25 gs per hour, and the effect of dose changes cannot be assessed for 8 to 12 hours, when peak serum levels are achieved. After removal of the patch, a subcutaneous reservoir of active drug remains whose half-life is approximately 18 hours. 76 Centrally acting analgesics are available in many formulations, including tablets, capsules, suppositories, drops, intravenous solutions, and, more recently, transdermal patches and lollipops. In the older patient population, route of administration is an even greater consideration than in a younger population, because of changes in skin integrity and gastrointestinal absorption and motility. Scrutiny of pharmacokinetics will be important and adjustments in dosing should be made accordingly. At times this will mean giving less medication than the minimum recommended dose.
Recent information on opioids indicates that binding of N-methyl-D-aspartate (NMDA) receptors may augment analgesia and diminish tolerance. 81 Short-acting opioids also may facilitate tolerance and thus lead to higher opioid dosage requirements for adequate pain control. 81, 82 Regardless of choice of opioid, route of administration, or dosing regimen, it is important to follow patients closely using a formal pain assessment tool (Table 2 provides an example of one such scale standardized in a senior population) in the first few days following a change in pain regimen so that serious adverse events can be avoided and, as importantly, so that pain relief can be achieved as quickly as possible. In the terminally ill patient, it is important to remember that manifestations of the dying process may present with symptoms that resemble opioid toxicity.
A final caution should be made regarding ordering an opioid antagonist, such as naloxone. If naloxone is to be used in a person who has been taking opioids for pain for a long time, administration can result in agony. If reversal of respiratory depression requires the use of naloxone, use a 1:10 dilution of the typical (0.04 mg/ml) dose and give 1 ml IV every 5 minutes until partial reversal occurs. Recognizing the short half-life of naloxone, this procedure may have to be repeated. 83 
Adverse Events
Adverse drug reactions occur more than twice as frequently among older adults than younger ones and increase as the number of medications increases. An older person taking six medications is 14 times more likely to have an adverse reaction than is a younger person on the same number of medications. 33, 84 Based on these statistics, any new medication should be carefully added to the drug regimen of an older patient.
The etiology of certain adverse reactions associated with centrally acting analgesics has been understood by differentiating the opioid receptors (, , ␦) to which specific agents bind. 20 Table 3 lists some of the receptors, examples of drugs that bind to each, primary locations, and actions. In the future, agents that bind on subreceptors may be able to promote analgesia without the adverse effects that are common to currently available agents. In the meantime, targeting specific receptors should be the goal when choosing opioid analgesics. Some adverse events, such as pruritus, may be associated with the amount of receptor binding, and the use of a more potent opioid (e.g., oxycodone or hydromorphone in place of morphine) may This scale incorporates three levels of assessment. First, pain is rated as "tolerable" or "intolerable." If pain is reported as intolerable, this should be considered an urgent matter and further evaluation and intervention rendered immediately, with frequent follow-up to assure improvement into the "tolerable" range as rapidly as possible. Second is a functional component. Some patients are likely to rank pain at the highest level, especially if apprehension over receiving adequate pain medication exists. With the FPS, the problem of having a patient always report pain at the highest level, 5, even when there is clearly improvement, is obviated. Because of the functional component associated with verbal communication, this instrument adjusts the score based on the fact that a person can verbally respond about pain. This functional portion of the scale provides a more objective component to the assessment and makes the instrument more sensitive to changes in pain level. Finally, the 0 to 5 scale presents a means of rapidly comparing with prior pain level responses (responsiveness). Ideally all patients should reach a 0 to 2 level, preferably 0 to 1. be a remedy or may be used to augment other interventions to control such adverse events. 85 Constipation is the one adverse event associated with opioids that can be expected to persist. For this reason, attention to a good bowel regimen is important in anyone taking opioids on a regular basis. Such a regimen should include adequate hydration, a bulk fiber product (to be avoided if adequate hydration cannot be maintained), and emphasizing mobility at whatever level is appropriate for the patient. A senna product is often helpful because of colonic receptor binding, which may make such an agent particularly useful with opioid-induced constipation. 86 When chronic cathartics must be used, an agent such as sorbitol (70%, 20 ml orally twice daily), will usually provide relief within days. Sorbitol may be particularly beneficial because of how well it is tolerated without long-term effects on the gastrointestinal tract. It also is relatively inexpensive. Occasionally, patients will request a similar product, lactulose, because of reimbursement coverage for this prescription brand of osmotic cathartic. The package insert for lactulose describes caution for this product in diabetics, although clinical data that justify excessive concern are wanting.
Selection of a particular opioid analgesic should be based on receptor action and route of administration. The nature of the pain also should be considered. Neuropathic pain, for example may not be as responsive to opioids as is pain of other etiologies. Morphine has a greater affinity for receptors than for other opioid receptors. The euphoria from the -opioid binding action of morphine is particularly useful for reducing anxiety and may have additional mechanisms for managing pain. Tolerance to sedation, respiratory depression, and emesis develops before tolerance to analgesia, therefore an agent like morphine may be better tolerated if the dose is gradually increased. 68 Because codeine also acts at the and receptors, precautions and benefits are similar to those of morphine. About 10% of people lack an enzyme necessary to metabolize codeine and thus may be refractory to the analgesic effect of codeine. Morphine at equianalgesic doses would be preferable in such individuals. Problems with meperidine have been described above.
Levorphanol and methadone have greater affinities for than receptors. The half-life exceeds the duration of analgesia. Consequently, excess sedation and respiratory depression may result. 18 These agents are poor choices for older patients. Because long-acting oral morphine and morphine-like, centrally acting analgesics are available, there is little reason to use methadone even in terminally ill patients with chronic pain.
All opioids deserve concern regarding urinary retention. This becomes particularly worrisome in older men with benign prostatic hypertrophy. Just as the sphincter of Oddi can be affected by opioid analgesics, an effect on the urethral sphincter with resultant bladder retention may occur with such agents as well. For this reason, it is important to regularly query patients taking opioids about urinary retention.
Suspected adverse events should be evaluated thoroughly. Reactions may often be misinterpreted as side effects from medication when such is not the case at all. For example, a patient who has been in pain for a long period of time may fall asleep from exhaustion once pain is finally relieved. All too often this is mistaken as a side effect of morphine. Normally, if respirations are found to be 12 breaths per minute or greater, the risk of respiratory depression is less likely. Other clues, such as miosis, should be present when opioid receptors are activated.
Dementia is common among older patients, and subclinical dementia may be unmasked by a prescription of opioids, particularly in a disorienting environment such as a hospital. [87] [88] [89] Using lower doses of opioids with a nonopioid adjuvant may be a strategy in such patients. 34 
Adjuvant Analgesics
Neuropathic pain is often poorly controlled by opioids alone, and many agents, including nortriptyline, clonazepam, carbamazepine, phenytoin, gabapentin, tramadol, and mexilitine, have reports of benefits for neuropathic pain. 90, 91 Other nonpharmacologic techniques, such as transcutaneous nerve stimulation, acupuncture, nerve blocks and radiation, also may be useful, depending on the etiology of the pain.
The anxiety that is associated with inadequate pain control may be a factor that makes pain management more difficult, as noted previously. Once the anxiety is eliminated, it is likely that less opioid will be necessary to maintain pain control than was necessary to resolve the patient's pain initially.
Tricyclic antidepressants (e.g., nortriptyline) are used commonly for neuropathy, but their use is limited by anticholinergic effects such as constipation, blurred vision, dry mouth, urinary retention, and sedation. Older patients may be at greater risk for such effects because of preexisting conditions (e.g., glaucoma, benign prostatic hypertrophy). Additional adverse effects of tricyclic antidepressants are arrhythmias, cognitive changes, and orthostatic hypotension. All can have potentially detrimental effects in the frail, older patient. Nortriptyline and desipramine have less cholinergic side effects than amitriptyline and are preferred for older patients. Anti-epileptic medications are also utilized to manage selected types of pain states, including trigeminal neuralgia (or glossopharyngeal neuralgia), which may occur more frequently in older patients. Carbamazepine may be effective when administered initially at 100 mg orally twice daily and increased to 800 mg per day as needed. If ineffective, phenytoin or clonazepam are good alternatives. The greatest concern with anti-epileptics in older patients is their propensity to cause falls and interfere with vitamin D metabolism, which is of particular concern in homebound older people. 62 In the past few years, gabapentin has increased in popularity as a good agent for neuropathic pain, with a relatively acceptable sideeffect profile. Dosing may begin as low as 100 mg per day but may need to be increased to 1500 mg or more per day in divided doses.
FUTURE OPTIONS
There is no question that the scientific community and the general public are in concert with the notion that we need better pain control in this country. New nonopioid painkillers, for example, ABT-594 (an Abbott Laboratories compound derived from the frog, Epipedobates tricolor), which acts via receptors for acetylcholine rather than on opioid receptors and may not have addictive potential, 92 and ziconotide (a Neurex compound from a sea snail), which blocks pain signals from entering the spinal cord, hold promise. 93 Legislation dealing with pain management is in the spotlight on Capitol Hill (e.g., S. 941, Conquering Pain Act of 1999 introduced by Senator Wyden with companion bill, HR 2188) and in state houses (e.g., legislation on inadequate pain management in Virginia and on protecting providers of pain management in Maryland). Finally, organizations that have traditionally dealt with pain and end-of-life issues are focusing efforts on education, and many are using access to the Internet as a mechanism to put out a worldwide message (see Table 4 ). All of these things make the prospect of better pain management even brighter for the future.
CONCLUSION
In general, with the geriatric population, the rule for dosing is to begin low and go slowly (see Table 5 ). Attaining appropriate use of opioids has been a tremendous obstacle in palliative care, both because of reluctance to use opioids and inappropriate prescribing. Pain is not a situation where an intervention can be prescribed and the patient asked to call back in a week. Most interventions will provide relief in hours to minutes. The use of some assessment tool to evaluate the level of pain and whether there has been a change is also important. Monitoring for adverse events is also critical. Patients need to know what to expect and when to expect it. Keep the lines of communication open and communicate often, especially at the beginning of a new regimen. • Obtain complete medical history with particular attention to: concurrent medications; prior adverse reactions; and concomitant illnesses.
• Resist prescribing without a diagnosis.
• Begin with low doses (often less than the minimum recommended dose) and increase slowly.
• Emphasize:
Continually review medications (including over-the-counter drugs). Decrease or remove medications when indicated.
